JP Morgan Maintains Overweight on Seaport Therapeutics, Raises Price Target to $41

Benzinga · 1d ago
JP Morgan analyst Tessa Romero maintains Seaport Therapeutics (NASDAQ:SPTX) with a Overweight and raises the price target from $40 to $41.